ADVERSE DRUG INTERACTIONS [[electronic resource] ] : a handbook for prescribers |
Edizione | [Second edition.] |
Pubbl/distr/stampa | [Place of publication not identified], : CRC Press, 2017 |
Descrizione fisica | 1 online resource (1,214 pages) |
Disciplina | 615.7/045 |
Soggetto topico |
Drugs - Side effects
Drug interactions |
ISBN |
0-429-58633-7
0-429-16002-X 1-4822-3622-2 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910154926203321 |
[Place of publication not identified], : CRC Press, 2017 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Antiseizure medication interactions : a clinical guide / / Philip N. Patsalos |
Autore | Patsalos Philip N. |
Edizione | [4th ed.] |
Pubbl/distr/stampa | Cham, Switzerland : , : Springer International Publishing, , [2022] |
Descrizione fisica | 1 online resource (327 pages) |
Disciplina | 615.7045 |
Soggetto topico |
Drug interactions
Drug interactions - Data processing Anticonvulsius Interaccions dels medicaments |
Soggetto genere / forma | Llibres electrònics |
ISBN | 3-030-82790-9 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910522937103321 |
Patsalos Philip N.
![]() |
||
Cham, Switzerland : , : Springer International Publishing, , [2022] | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde |
Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
Descrizione fisica | 1 online resource (506 p.) |
Disciplina | 615.704 |
Altri autori (Persone) |
VazRoy J
KlabundeThomas |
Collana | Methods and principles in medicinal chemistry |
Soggetto topico |
Drugs - Side effects
Drugs - Side effects - Prevention Drug interactions Drug development Drugs - Structure-activity relationships |
Soggetto genere / forma | Electronic books. |
ISBN |
1-282-78430-7
9786612784309 3-527-62147-4 3-527-62146-6 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Antitargets; Contents; List of Contributors; Preface; I General Aspects; 1 Why Drugs Fail - A Study on Side Effects in New Chemical Entities; 1.1 Introduction; 1.2 Drugs Withdrawn from the Market between 1992 and 2006 Listed Alphabetically; 1.2.1 Amineptine; 1.2.2 Aminophenazone (Aminopyrine); 1.2.3 Astemizole; 1.2.4 Bromfenac Sodium; 1.2.5 Cerivastatin; 1.2.6 Chlormezanone; 1.2.7 Fenfluramine and Dexfenfluramine; 1.2.8 Flosequinan; 1.2.9 Glafenine; 1.2.10 Grepafloxacin; 1.2.11 Levacetylmethadol; 1.2.12 Mibefradil; 1.2.13 Rapacuronium Bromide; 1.2.14 Rofecoxib; 1.2.15 Temafloxacin
1.2.16 Troglitazone1.2.17 Ximelagatran; 1.3 Borderline Cases; 1.4 Investigational Drugs That Failed in Clinical Phases from 1992 to 2002; 1.4.1 A Case Study: Fialuridine; 1.4.2 A Recent Case Study: Torcetrapib; 1.4.3 General Reasons for Project Failing in Clinical Phases I-III; 1.5 Strategies for Avoiding Failure; 1.6 An Unusual Case: The Revival of Thalidomide; References; 2 Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure-In Vitro (Pharmacology-ADME)-In Vivo (Safety) Relationships; 2.1 Introduction 2.1.1 Biological Profiling/Fingerprints and Drug Discovery Applications2.1.2 Polypharmacology of Drugs; 2.2 The BioPrint(®) Approach; 2.2.1 BioPrint(®) - General; 2.2.2 BioPrint(®) Assay Selection and Profile Description; 2.2.3 Compounds in BioPrint(®); 2.2.4 BioPrint(®) In Vivo Data sets; 2.2.4.1 Compound Details; 2.2.4.2 ADR Data; 2.2.4.3 Pharmacokinetics; 2.2.4.4 Toxicity Data; 2.3 Structure-In Vitro Relationships; 2.3.1 Similarity, Chemotypes - What Is a Biologically Relevant Descriptor?; 2.3.2 Using Biological Fingerprints as a Meaningful Descriptor for Drug Leads and Candidates 2.3.2.1 Differentiation of Leads2.3.2.2 Analysis of Attrited Compounds; 2.3.3 Structural versus Experimental Differentiation - Dependence on Structure-Derived Descriptor Used; 2.3.4 Predictive Models from Pharmacological Data; 2.3.5 Predictive Models from ADME Data - BioPrint(®) Learnings; 2.4 Chemogenomic Analysis - Target-Target Relationships; 2.5 In Vitro-In Vivo Relationships - Placing Drug Candidates in the Context of BioPrint(®); 2.5.1 Analyzing Potential ADR Liabilities Based on Individual Hits; 2.5.2 Analyzing Potential ADR Liabilities Based on Profile Similarity 2.6 A Perspective for the FutureReferences; II Antitargets: Ion Channels and GPCRs; 3 Pharmacological and Regulatory Aspects of QT Prolongation; 3.1 Introduction; 3.2 hERG: Target Versus Antitarget; 3.3 Pharmacology of QT Prolongation; 3.3.1 Multiple Mechanisms Leading to QT Prolongation; 3.3.2 hERG as the Key Mechanism for the Drug-Induced Long QT Syndrome; 3.3.3 Pharmacogenetic Aspects; 3.4 Significance of Drug-Induced QT Prolongation; 3.4.1 Prolonged QT/QTc and Occurrence of TdP; 3.4.2 Dose-Response Relationship for QT Prolongation; 3.5 Regulatory Aspects of QT Prolongation 3.5.1 Regulatory Guidance Documents |
Record Nr. | UNINA-9910145982103321 |
Weinheim, : Wiley-VCH | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde |
Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
Descrizione fisica | 1 online resource (506 p.) |
Disciplina | 615.704 |
Altri autori (Persone) |
VazRoy J
KlabundeThomas |
Collana | Methods and principles in medicinal chemistry |
Soggetto topico |
Drugs - Side effects
Drugs - Side effects - Prevention Drug interactions Drug development Drugs - Structure-activity relationships |
ISBN |
1-282-78430-7
9786612784309 3-527-62147-4 3-527-62146-6 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Antitargets; Contents; List of Contributors; Preface; I General Aspects; 1 Why Drugs Fail - A Study on Side Effects in New Chemical Entities; 1.1 Introduction; 1.2 Drugs Withdrawn from the Market between 1992 and 2006 Listed Alphabetically; 1.2.1 Amineptine; 1.2.2 Aminophenazone (Aminopyrine); 1.2.3 Astemizole; 1.2.4 Bromfenac Sodium; 1.2.5 Cerivastatin; 1.2.6 Chlormezanone; 1.2.7 Fenfluramine and Dexfenfluramine; 1.2.8 Flosequinan; 1.2.9 Glafenine; 1.2.10 Grepafloxacin; 1.2.11 Levacetylmethadol; 1.2.12 Mibefradil; 1.2.13 Rapacuronium Bromide; 1.2.14 Rofecoxib; 1.2.15 Temafloxacin
1.2.16 Troglitazone1.2.17 Ximelagatran; 1.3 Borderline Cases; 1.4 Investigational Drugs That Failed in Clinical Phases from 1992 to 2002; 1.4.1 A Case Study: Fialuridine; 1.4.2 A Recent Case Study: Torcetrapib; 1.4.3 General Reasons for Project Failing in Clinical Phases I-III; 1.5 Strategies for Avoiding Failure; 1.6 An Unusual Case: The Revival of Thalidomide; References; 2 Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure-In Vitro (Pharmacology-ADME)-In Vivo (Safety) Relationships; 2.1 Introduction 2.1.1 Biological Profiling/Fingerprints and Drug Discovery Applications2.1.2 Polypharmacology of Drugs; 2.2 The BioPrint(®) Approach; 2.2.1 BioPrint(®) - General; 2.2.2 BioPrint(®) Assay Selection and Profile Description; 2.2.3 Compounds in BioPrint(®); 2.2.4 BioPrint(®) In Vivo Data sets; 2.2.4.1 Compound Details; 2.2.4.2 ADR Data; 2.2.4.3 Pharmacokinetics; 2.2.4.4 Toxicity Data; 2.3 Structure-In Vitro Relationships; 2.3.1 Similarity, Chemotypes - What Is a Biologically Relevant Descriptor?; 2.3.2 Using Biological Fingerprints as a Meaningful Descriptor for Drug Leads and Candidates 2.3.2.1 Differentiation of Leads2.3.2.2 Analysis of Attrited Compounds; 2.3.3 Structural versus Experimental Differentiation - Dependence on Structure-Derived Descriptor Used; 2.3.4 Predictive Models from Pharmacological Data; 2.3.5 Predictive Models from ADME Data - BioPrint(®) Learnings; 2.4 Chemogenomic Analysis - Target-Target Relationships; 2.5 In Vitro-In Vivo Relationships - Placing Drug Candidates in the Context of BioPrint(®); 2.5.1 Analyzing Potential ADR Liabilities Based on Individual Hits; 2.5.2 Analyzing Potential ADR Liabilities Based on Profile Similarity 2.6 A Perspective for the FutureReferences; II Antitargets: Ion Channels and GPCRs; 3 Pharmacological and Regulatory Aspects of QT Prolongation; 3.1 Introduction; 3.2 hERG: Target Versus Antitarget; 3.3 Pharmacology of QT Prolongation; 3.3.1 Multiple Mechanisms Leading to QT Prolongation; 3.3.2 hERG as the Key Mechanism for the Drug-Induced Long QT Syndrome; 3.3.3 Pharmacogenetic Aspects; 3.4 Significance of Drug-Induced QT Prolongation; 3.4.1 Prolonged QT/QTc and Occurrence of TdP; 3.4.2 Dose-Response Relationship for QT Prolongation; 3.5 Regulatory Aspects of QT Prolongation 3.5.1 Regulatory Guidance Documents |
Record Nr. | UNINA-9910830632603321 |
Weinheim, : Wiley-VCH | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde |
Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
Descrizione fisica | 1 online resource (506 p.) |
Disciplina | 615.704 |
Altri autori (Persone) |
VazRoy J
KlabundeThomas |
Collana | Methods and principles in medicinal chemistry |
Soggetto topico |
Drugs - Side effects
Drugs - Side effects - Prevention Drug interactions Drug development Drugs - Structure-activity relationships |
ISBN |
1-282-78430-7
9786612784309 3-527-62147-4 3-527-62146-6 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Antitargets; Contents; List of Contributors; Preface; I General Aspects; 1 Why Drugs Fail - A Study on Side Effects in New Chemical Entities; 1.1 Introduction; 1.2 Drugs Withdrawn from the Market between 1992 and 2006 Listed Alphabetically; 1.2.1 Amineptine; 1.2.2 Aminophenazone (Aminopyrine); 1.2.3 Astemizole; 1.2.4 Bromfenac Sodium; 1.2.5 Cerivastatin; 1.2.6 Chlormezanone; 1.2.7 Fenfluramine and Dexfenfluramine; 1.2.8 Flosequinan; 1.2.9 Glafenine; 1.2.10 Grepafloxacin; 1.2.11 Levacetylmethadol; 1.2.12 Mibefradil; 1.2.13 Rapacuronium Bromide; 1.2.14 Rofecoxib; 1.2.15 Temafloxacin
1.2.16 Troglitazone1.2.17 Ximelagatran; 1.3 Borderline Cases; 1.4 Investigational Drugs That Failed in Clinical Phases from 1992 to 2002; 1.4.1 A Case Study: Fialuridine; 1.4.2 A Recent Case Study: Torcetrapib; 1.4.3 General Reasons for Project Failing in Clinical Phases I-III; 1.5 Strategies for Avoiding Failure; 1.6 An Unusual Case: The Revival of Thalidomide; References; 2 Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure-In Vitro (Pharmacology-ADME)-In Vivo (Safety) Relationships; 2.1 Introduction 2.1.1 Biological Profiling/Fingerprints and Drug Discovery Applications2.1.2 Polypharmacology of Drugs; 2.2 The BioPrint(®) Approach; 2.2.1 BioPrint(®) - General; 2.2.2 BioPrint(®) Assay Selection and Profile Description; 2.2.3 Compounds in BioPrint(®); 2.2.4 BioPrint(®) In Vivo Data sets; 2.2.4.1 Compound Details; 2.2.4.2 ADR Data; 2.2.4.3 Pharmacokinetics; 2.2.4.4 Toxicity Data; 2.3 Structure-In Vitro Relationships; 2.3.1 Similarity, Chemotypes - What Is a Biologically Relevant Descriptor?; 2.3.2 Using Biological Fingerprints as a Meaningful Descriptor for Drug Leads and Candidates 2.3.2.1 Differentiation of Leads2.3.2.2 Analysis of Attrited Compounds; 2.3.3 Structural versus Experimental Differentiation - Dependence on Structure-Derived Descriptor Used; 2.3.4 Predictive Models from Pharmacological Data; 2.3.5 Predictive Models from ADME Data - BioPrint(®) Learnings; 2.4 Chemogenomic Analysis - Target-Target Relationships; 2.5 In Vitro-In Vivo Relationships - Placing Drug Candidates in the Context of BioPrint(®); 2.5.1 Analyzing Potential ADR Liabilities Based on Individual Hits; 2.5.2 Analyzing Potential ADR Liabilities Based on Profile Similarity 2.6 A Perspective for the FutureReferences; II Antitargets: Ion Channels and GPCRs; 3 Pharmacological and Regulatory Aspects of QT Prolongation; 3.1 Introduction; 3.2 hERG: Target Versus Antitarget; 3.3 Pharmacology of QT Prolongation; 3.3.1 Multiple Mechanisms Leading to QT Prolongation; 3.3.2 hERG as the Key Mechanism for the Drug-Induced Long QT Syndrome; 3.3.3 Pharmacogenetic Aspects; 3.4 Significance of Drug-Induced QT Prolongation; 3.4.1 Prolonged QT/QTc and Occurrence of TdP; 3.4.2 Dose-Response Relationship for QT Prolongation; 3.5 Regulatory Aspects of QT Prolongation 3.5.1 Regulatory Guidance Documents |
Record Nr. | UNINA-9910841023103321 |
Weinheim, : Wiley-VCH | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Antitargets and drug safety / / edited by Lásló Urbán, Vinod F. Patel, and Roy J. Vaz |
Pubbl/distr/stampa | Weinheim, Germany : , : Wiley-VCH, , [2015] |
Descrizione fisica | 1 online resource (1266 p.) |
Disciplina | 615.19 |
Collana | Methods and principles in medicinal chemistry |
Soggetto topico |
Drugs - Side effects
Drugs - Side effects - Prevention Drug interactions Drug development Drugs - Structure-activity relationships Drug-Related Side Effects and Adverse Reactions Protein Kinase Inhibitors - adverse effects Pharmacovigilance |
ISBN |
3-527-67364-4
3-527-67366-0 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | section 1. General concept for target-based safety assessment -- section 2. Hepatic side effects -- section 3. Cardiovascular side effects -- section 4. Kinase antitargets -- section 5. Examples of clinical translation. |
Record Nr. | UNINA-9910132261703321 |
Weinheim, Germany : , : Wiley-VCH, , [2015] | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Antitargets and drug safety / / edited by Lásló Urbán, Vinod F. Patel, and Roy J. Vaz |
Pubbl/distr/stampa | Weinheim, Germany : , : Wiley-VCH, , [2015] |
Descrizione fisica | 1 online resource (1266 p.) |
Disciplina | 615.19 |
Collana | Methods and principles in medicinal chemistry |
Soggetto topico |
Drugs - Side effects
Drugs - Side effects - Prevention Drug interactions Drug development Drugs - Structure-activity relationships Drug-Related Side Effects and Adverse Reactions Protein Kinase Inhibitors - adverse effects Pharmacovigilance |
ISBN |
3-527-67364-4
3-527-67366-0 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | section 1. General concept for target-based safety assessment -- section 2. Hepatic side effects -- section 3. Cardiovascular side effects -- section 4. Kinase antitargets -- section 5. Examples of clinical translation. |
Record Nr. | UNINA-9910823349403321 |
Weinheim, Germany : , : Wiley-VCH, , [2015] | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Applications of Mass Spectrometry in Microbiology [[electronic resource] ] : From Strain Characterization to Rapid Screening for Antibiotic Resistance / / edited by Plamen Demirev, Todd R. Sandrin |
Edizione | [1st ed. 2016.] |
Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 |
Descrizione fisica | 1 online resource (336 p.) |
Disciplina | 540 |
Soggetto topico |
Mass spectrometry
Microbiology Epidemiology Drug interactions Mass Spectrometry Applied Microbiology Drug Resistance |
ISBN | 3-319-26070-7 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Introduction -- SECTION I. METHODOLOGY AND TECHNIQUES.- Methods and instrumentation in mass spectrometry for the differentiation of closely related microorganisms.- Sample preparation methods for the rapid MS analysis of microorganisms.- Advantages offered by proteomic strategies for rapid biodetection.- Bottom Up Proteomics Methods for Strain-Level Typing and Identification of Bacteria.- Maximizing the taxonomic resolution of MALDI-TOF-MS-based approaches to bacterial characterization: From culture conditions through data analysis -- SECTION II. SUB-SPECIES DISCRIMINATION.- Modulation of the Discriminatory Power of MALDI-TOF MS Profiling for Distinguishing between Closely Related Bacterial Strains.- Discriminatory Power of MALDI-TOF Mass Spectrometry for Phylogenetically Closely Related Microbial Strains.- MALDI-TOF MS as a novel tool for dereplication and characterization of microbiota in bacterial diversity studies.- Bacterial Identification at the Serovar level by Top-down Mass Spectrometry -- SECTION III. DRUG RESISTANCE MONITORING AND ASSAYS.- Rapid profiling of human pathogenic bacteria and antibiotic resistance employing specific tryptic peptides as biomarkers.- Detection of β-lactamases and their activity using MALDI-TOF MS.- Stable-isotope based strategies for rapid determination of drug resistance by mass spectrometry. |
Record Nr. | UNINA-9910254053303321 |
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Dangerous drug interactions |
Pubbl/distr/stampa | [Rockville, Md.] : , : Department of Health & Human Services, Substance Abuse and Mental Health Services Administration |
Descrizione fisica | 1 online resource (1 unnumbered page) : illustrations |
Collana |
Rx pain medications: know the options, get the facts
SMA |
Soggetto topico |
Drug interactions
Opioids - Administration Drugs - Prescribing - Management Pain - Treatment - Management Pain medicine |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910716900603321 |
[Rockville, Md.] : , : Department of Health & Human Services, Substance Abuse and Mental Health Services Administration | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Drug interactions in psychiatry / / edited by Domenic A. Ciraulo [and three others] |
Edizione | [Third edition.] |
Pubbl/distr/stampa | Philadelphia : , : Lippincott Williams & Wilkins, , [2006] |
Descrizione fisica | 1 online resource (454 pages) : illustrations |
Disciplina | 615/.788 |
Altri autori (Persone) | CirauloDomenic A |
Soggetto topico |
Psychotropic drugs - Side effects
Drug interactions |
Soggetto genere / forma | Electronic books. |
ISBN | 1-4511-6635-4 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Concepts and mechanisms of drug disposition and drug interactions -- Antidepressants -- Antipsychotics -- Lithium -- Anticonvulsants -- Electroconvulsive therapy -- Drug ineractions of importance in substance abuse -- Interactions of psychotropics with herbals -- Drugs (including metabolites) that are substrates of cytochrome P450. |
Record Nr. | UNINA-9910456954103321 |
Philadelphia : , : Lippincott Williams & Wilkins, , [2006] | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|